Company Overview of Prosensa Holding N.V.
Prosensa Holding N.V., a biotechnology company, engages in the discovery and development of ribonucleic acid-modulating therapeutics for the treatment of genetic disorders. The company’s products focus on the treatment of neuromuscular and neurodegenerative disorders, including duchenne muscular dystrophy (DMD), myotonic dystrophy, and huntington’s diseases. It develops drisapersen, which is in Phase III studies to restore dystrophin expression and enhancing muscle condition; PRO044 that is in Phase I/II studies to address a separate sub-population of DMD patients; and PRO045, PRO053, PRO052, and PRO055 to address other distinct sub-populations of DMD patients. The company also develops PRO1...
J.H. Oortweg 21
Leiden, 2333 CH
Founded in 1997
Key Executives for Prosensa Holding N.V.
Chief Executive Officer and Member of Management Board
Co-Founder and Scientific Director
Founder, Chief Development Officer and Member of Scientific & Clinical Advisory Board
Chief Financial Officer, Principal Accounting Officer and Member of Management Board
Chief Business Officer, Senior Vice President of Business Development and Member of Management Board
Compensation as of Fiscal Year 2014.
Prosensa Holding N.V. Key Developments
Prosensa Holding N.V.(NasdaqGS:RNA) dropped from NASDAQ Composite Index
Feb 11 15
Prosensa Holding N.V. will be removed from NASDAQ Composite Index.
Prosensa Holding N.V. Announces Advance Liquidation Distribution
Feb 10 15
Prosensa Holding N.V. announced that based on Asset Sale, the company will make an advance liquidation distribution to its remaining shareholders with each remaining shareholder receiving a cash payment equal to $17.75 per Share as well as one contingent value right to receive cash payments of up to $4.14 per Share in the aggregate upon the achievement of certain product approval milestones, without interest thereon and less any applicable withholding taxes.
Prosensa Announces Intent To Voluntarily Delist From NASDAQ
Jan 30 15
Prosensa Holding N.V. announced today that it intends to voluntarily delist the registered shares of the Company, nominal value €0.01 per share (the "Shares"), from the NASDAQ Global Select Market ("NASDAQ"). Upon satisfaction of the applicable requirements for deregistration, Prosensa also intends to deregister the Shares under the Securities Exchange Act of 1934, as amended (the "Exchange Act") and to suspend its reporting obligations under the Exchange Act once it is eligible to do so.
Similar Private Companies By Industry
Recent Private Companies Transactions
November 24, 2014
August 11, 2014
Most Searched Private Companies
Sponsored Financial Commentaries